Dr. Cameron Turtle is the CEO of Aeglea BioTherapeutics, having stepped into the role in October 2023 after serving as the company's Chief Operating Officer since June 2023. He has an impressive background in biopharma, with a focus on bringing...

Dr. Cameron Turtle is the CEO of Aeglea BioTherapeutics, having stepped into the role in October 2023 after serving as the company's Chief Operating Officer since June 2023. He has an impressive background in biopharma, with a focus on bringing medical innovations to life. Dr. Turtle earned his B.S. in Bioengineering from the University of Washington and a D.Phil. in Cardiovascular Medicine from the University of Oxford. He has a track record of building companies in the biotech space, including roles at Eidos Therapeutics and BridgeBio Pharma. Notably, he has contributed to successful drug development initiatives and has experience in business strategy at a high level. His work led to several award recognitions, like being named in Forbes' 30 Under 30 list. In 2023, his total compensation rose to $7,802,03, showcasing his significance in the firm post-promotion.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Spyre Therapeutics, Inc. CEOs

S

Cameron Turtle

CEO of Spyre Therapeutics, Inc.

Education

B.S. in Bioengineering from the University of Washington, D.Phil. in Cardiovascular Medicine from the University of Oxford.

Sector of Economy

Healthcare

CEO of Spyre Therapeutics, Inc. for

1 year 7 months (Oct 2023 - Present)

Previous Experience

Venture Partner at Foresite Labs, Chief Strategy Officer of BridgeBio Pharma, Chief Business Officer of Eidos Therapeutics.

Rivals

Competitors/colleagues of Cameron Turtle

Holdings

See how much did Cameron Turtle make over time.

Dr. Cameron Turtle's insider trading history shows significant stock activities over the years, indicating a solid commitment to his company’s future. In January 2020, he made a remarkable transaction worth over $10 million, which marked one of his highest trades....

Dr. Cameron Turtle's insider trading history shows significant stock activities over the years, indicating a solid commitment to his company’s future. In January 2020, he made a remarkable transaction worth over $10 million, which marked one of his highest trades. Following that, he had several months of similar high-value transactions continuing into 2021, often exceeding $4 million nearly every month. After a quieter period in 2022, the trend picked up again in 2023 with trades averaging around $600,000 monthly, peaking at $2.58 million in January 2024. His holdings reflect confidence in Spyre Therapeutics and a vested interest in its growth and success.

Total Stock Sold

$3.61M

BBIO

$3.61M

83,307 BBIO shares

What if they kept their stock?

If Cameron Turtle didn't sell their stock, today they would have:
Extra BBIO83,307 shares worth $2.76M.
This is -23.77% and $859.10K less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Cameron Turtle.

BBIO

$1.36M

BBIO at $69.64/share

Dec 28, 2020

Sale

BBIO

$235.58K

BBIO at $47.12/share

Nov 24, 2020

Sale

BBIO

$105.12K

BBIO at $42.05/share

Nov 5, 2020

Sale

BBIO

$549.83K

BBIO at $37.92/share

Sep 30, 2020

Sale

BBIO

$105.02K

BBIO at $42.01/share

Sep 18, 2020

Sale

BBIO

$92.65K

BBIO at $37.06/share

Sep 15, 2020

Sale

BBIO

$70.05K

BBIO at $35.02/share

Sep 11, 2020

Sale

BBIO

2,745 shares

BBIO

Sep 1, 2020

Received

BBIO

$329.10K

BBIO at $32.91/share

Jun 30, 2020

Sale

BBIO

$64.03K

BBIO at $32.01/share

Apr 27, 2020

Sale

Compensation History

See how much did Cameron Turtle make over time.

In 2023, Dr. Turtle's total compensation was $780,203, which includes a base salary of $625,000 and a discretionary bonus of $141,000. In addition to this cash compensation, he saw significant increases in his equity holdings with $5,080,73 in vested stock. His total compensation reflects the company’s strategy to incentivize top leaders with a mix of salary and stock awards, aiming for long-term growth. Performance metrics play a key role in determining his pay, tying his financial success to the company’s overall performance and strategic goals.

Year

2023

Total Compensation

$11.70M

Salary

$625.00K

Board Justification

The compensation philosophy aims to attract and retain key employees for the Company’s continued success and growth, balancing internal and external alignment.

Bonus

$141.00K

Board Justification

Discretionary annual bonus for 2023.

Other

$5.20K

Board Justification

Matching contributions under the 401(k) plan made during 2023.

Restricted Stock

$10.93M(508.07K restricted common stock)

Board Justification

Shares of restricted common stock that vested in 2023, reflecting the vesting schedule of the stock awards.

Performance Metrics

The performance metrics for determining compensation include the achievement of corporate goals and objectives relevant to the compensation of the CEO.

Other Spyre Therapeutics, Inc. CEOs

Here are other CEOs of Spyre Therapeutics, Inc.

James Kastenmayer

Ex-CEO of Spyre Therapeutics, Inc.

August 2022 - October 2023